.png | CAS_number = 50-91-9 | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = 5790 | DrugBank = APRD00692 | chemical_formula = C₉H₁₁FN₂O₅ | molecular_weight = 246.193 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }} Floxuridine is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colectoral cancer.

Pharmacology

---

Floxuridine, an analog of 5-Fluorouracil, is a fluorinated pyrimidine.

Meachanism of action

---

Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.

History

---

Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-flurouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to Faulding, which became Mayne Pharma.

Suppliers

---

In the US the drug is supplied by Mayne Pharma as well as APP and Bedford.

Chemotherapeutic agents